These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

103 related items for PubMed ID: 8558918

  • 1. Establishment of a human B-CLL xenograft model: utility as a preclinical therapeutic model.
    Mohammad RM, Mohamed AN, Hamdan MY, Vo T, Chen B, Katato K, Abubakr YA, Dugan MC, al-Katib A.
    Leukemia; 1996 Jan; 10(1):130-7. PubMed ID: 8558918
    [Abstract] [Full Text] [Related]

  • 2. Sequential treatment of human chronic lymphocytic leukemia with bryostatin 1 followed by 2-chlorodeoxyadenosine: preclinical studies.
    Mohammad RM, Katato K, Almatchy VP, Wall N, Liu KZ, Schultz CP, Mantsch HH, Varterasian M, al-Katib AM.
    Clin Cancer Res; 1998 Feb; 4(2):445-53. PubMed ID: 9516935
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Establishment of a human pancreatic tumor xenograft model: potential application for preclinical evaluation of novel therapeutic agents.
    Mohammad RM, Dugan MC, Mohamed AN, Almatchy VP, Flake TM, Dergham ST, Shields AF, Al-Katib AA, Vaitkevicius VK, Sarkar FH.
    Pancreas; 1998 Jan; 16(1):19-25. PubMed ID: 9436858
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. In vitro and In vivo selective antitumor activity of Edelfosine against mantle cell lymphoma and chronic lymphocytic leukemia involving lipid rafts.
    Mollinedo F, de la Iglesia-Vicente J, Gajate C, Estella-Hermoso de Mendoza A, Villa-Pulgarin JA, de Frias M, Roué G, Gil J, Colomer D, Campanero MA, Blanco-Prieto MJ.
    Clin Cancer Res; 2010 Apr 01; 16(7):2046-54. PubMed ID: 20233887
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Treatment of a de novo fludarabine resistant-CLL xenograft model with bryostatin 1 followed by fludarabine.
    Mohammad RM, Limvarapuss C, Hamdy N, Dutcher BS, Beck FW, Wall NR, Al-Katib AM.
    Int J Oncol; 1999 May 01; 14(5):945-50. PubMed ID: 10200346
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Engraftment of chronic prolymphocytic and T cell leukemia in SCID mice.
    O'Brien S, Jeha S, Kantarjian H, Pisa P, Jin G, Keating M, Beran M.
    Leukemia; 1996 Feb 01; 10(2):338-44. PubMed ID: 8637244
    [Abstract] [Full Text] [Related]

  • 16. Soluble CD200 is critical to engraft chronic lymphocytic leukemia cells in immunocompromised mice.
    Wong KK, Brenneman F, Chesney A, Spaner DE, Gorczynski RM.
    Cancer Res; 2012 Oct 01; 72(19):4931-43. PubMed ID: 22875025
    [Abstract] [Full Text] [Related]

  • 17. Alkylator resistance in human B lymphoid cell lines: (1). Melphalan accumulation, cytotoxicity, interstrand-DNA-crosslinks, cell cycle analysis, and glutathione content in the melphalan-sensitive B-lymphocytic cell line (WIL2) and in the melphalan-resistant B-CLL cell line (WSU-CLL).
    Pu Q, Bianchi P, Bezwoda WR.
    Anticancer Res; 2000 Oct 01; 20(4):2561-8. PubMed ID: 10953327
    [Abstract] [Full Text] [Related]

  • 18. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
    Lindhagen E, Norberg M, Kanduri M, Tobin G, Säisänen L, Aberg M, Gustafsson MG, Sundström C, Rosenquist R, Aleskog A.
    Eur J Haematol; 2009 Jul 01; 83(1):22-34. PubMed ID: 19245531
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bcl-2 antisense oligonucleotides are effective against systemic but not central nervous system disease in severe combined immunodeficient mice bearing human t(14;18) follicular lymphoma.
    Mohammad R, Abubakr Y, Dan M, Aboukameel A, Chow C, Mohamed A, Hamdy N, Al-Katib A.
    Clin Cancer Res; 2002 Apr 01; 8(4):1277-83. PubMed ID: 11948143
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.